ArticleFrontiers in cardiovascular medicine2026
Impact of COVID-19 history on the prevalence of coronary slow flow: a comparative study in unstable angina patients.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study investigated coronary slow flow (CSF) prevalence in post-COVID-19 patients presenting with unstable angina (UA) and angiographically normal coronary arteries. Materials and methods: The study included 190 patients presenting with unstable angina (UA) and confirmed normal coronary arteries via invasive angiography. Participants were divided into two age- and sex-matched groups: 95 patients with a history of COVID-19 [COVID (+) UA-NCA] and 95 patients without a prior history of the infection [COVID (-) UA-NCA]. In the study group, COVID-19 was confirmed via RT-PCR and computed tomography. All participants underwent coronary angiography to perform Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) measurements. CSF was diagnosed in patients with a corrected TFC (CTFC) ≥ 27. Results: CSF prevalence was significantly higher in the COVID (+) UA-NCA group than in the COVID (-) UA-NCA group (18.9% vs. 5.3%, Conclusions: CSF prevalence is significantly higher in patients with a history of COVID-19, suggesting persistent microvascular impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.